European Biotechs benefit from public equity offerings in the U.S.

Without a doubt, our analysis confirms the hypothesis that U.S. stock exchanges are more attractive for Biotech companies seeking public equity due to a larger capital environment with a higher number of investors and research analysts.

The table shows that during the last five years, U.S. stock exchanges hosted 3 times more Biotech IPOs than European stock exchanges. In addition, the average IPO volume was about 6 times higher.

Overall, total public equity raised by European and U.S. Biotech companies on U.S. exchanges via IPOs and follow-on offerings is roughly 5 times higher compared to their European counterparts.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: